Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/vaccines10020291 http://scihub22266oqcxt.onion/10.3390/vaccines10020291 35214749!8879449!35214749     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Vaccines+(Basel) 2022 ; 10 (2): ä Nephropedia Template TP {{tp|p=35214749|t=2022. Neutralization of SARS-CoV-2 Variants by rVSV-DeltaG-Spike-Elicited Human Sera |pdf=|usr=}}{{35214749}} gab.com Text Neutralization of SARS-CoV-2 Variants by rVSV-DeltaG-Spike-Elicited Human Sera JO: Vaccines (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=35214749 #FOAvip The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife((R)) (rVSV-DeltaG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-DeltaG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants' mutations. We show that human sera from BriLife((R)) vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife((R)) vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife((R))-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs. Twit Text FOAVip Neutralization of SARS-CoV-2 Variants by rVSV-DeltaG-Spike-Elicited Human Sera ????Vaccines (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=35214749 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35214749 #FOAvip English Wikipedia <ref>{{Cite pmid|35214749}}</ref> Neutralization of SARS-CoV-2 Variants by rVSV-DeltaG-Spike-Elicited Human Sera #MMPMID35214749 Yahalom-Ronen Y; Erez N; Fisher M; Tamir H; Politi B; Achdout H; Melamed S; Glinert I; Weiss S; Cohen-Gihon I; Israeli O; Izak M; Mandelboim M; Caraco Y; Madar-Balakirski N; Mechaly A; Shinar E; Zichel R; Cohen D; Beth-Din A; Zvi A; Marcus H; Israely T; Paran N Vaccines (Basel) 2022[Feb]; 10 (2): ä PMID35214749show ga The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife((R)) (rVSV-DeltaG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-DeltaG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants' mutations. We show that human sera from BriLife((R)) vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife((R)) vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife((R))-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs. äNeutralization of SARS-CoV-2 Variants by rVSV-DeltaG-Spike-Elicited Hu(epmc).pdf DeepDyve Pubget Overpricing